allergy banner

EAACI Guidelines

To add the references below to your reference management program: 1. Download the file; 2. Open your reference management program or EndNote; 3. Select File and import

Download references for EndNote

Download references for others

28 Articles

EAACI guidelines on environmental science in allergic diseases and asthma – Leveraging artificial intelligence and machine learning to develop a causality model in exposomics

Shamji, MH, Ollert, M, Adcock, IM, et al. Allergy. First published: 05 February 2023

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis and management of urticaria

Zuberbier, T., Abdul Latiff, A., Abuzakouk, M., et al. Allergy. First published: 18 September 2021

EAACI biologicals guidelines – Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Agache, I., Akdis, C., Akdis, M., et al. Allergy. First published: 29 July 2021

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

Maurer, M, Magerl, M, Betschel, S, et al. Allergy. 2022; 77: 1961– 1990

World Health Organization global air quality guideline recommendations: Executive summary

Goshua, A, Akdis, C, Nadeau, KC. Allergy. 2022; 77: 1955– 1960

EAACI guidelines: Anaphylaxis (2021 update)

Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377

Dissemination of EAACI food allergy guidelines using a flexible, practical, whole school allergy awareness toolkit

Higgs, J., Styles, K., Bowyer, S., et al. Allergy. 2021; 76: 3479-3488

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Agache, I., Song, Y., Alonso-Coello, P., et al. Allergy. 2021; 76: 2337-2353

EAACI biologicals guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

Agache, I., Akdis, C.A., Akdis, M., et al. Allergy. 2021; 76: 988-1009

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI biologicals guidelines

Agache, I, Rocha, C, Pereira, A, et al. Allergy. 2021; 76: 59– 70

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma

Agache, I, Song, Y, Posso, M, et al. Allergy. 2021; 76: 45– 58

EAACI biologicals guidelines—recommendations for severe asthma

Agache, I, Akdis, CA, Akdis, M, et al. Allergy. 2021; 76: 14– 44

EAACI guideline on the effective transition of adolescents and young adults with allergy and asthma

Roberts, G, Vazquez-Ortiz, M, Knibb, R, et al. Allergy. 2020; 75: 2734– 2752

Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma

Agache, I, Song, Y, Rocha, C, et al. Allergy. 2020; 75: 1058– 1068

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Agache, I, Rocha, C, Beltran, J, et al. Allergy. 2020; 75: 1043– 1057

Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

Agache, I, Beltran, J, Akdis, C, et al. Allergy. 2020; 75: 1023– 1042

EAACI guidelines on allergen immunotherapy: House dust mite-driven allergic asthma

Agache, I, Lau, S, Akdis, CA, et al. Allergy. 2019; 74: 855– 873

et al. Allergy.

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update

Maurer, M, Magerl, M, Ansotegui, I, et al. et al. Allergy. 2018; 73: 1575– 1596.

EAACI Guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis

Roberts, G, Pfaar, O, Akdis, CA, et al. Allergy. 2018; 73: 765– 798

EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy

Pajno, GB, Fernandez-Rivas, M, Arasi, S, et al. Allergy. 2018; 73: 799– 815

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

Sturm, GJ, Varga, E-M, Roberts, G, et al. Allergy. 2018; 73: 744– 764

EAACI guidelines on allergen immunotherapy: Executive statement

Muraro, A., Roberts, G., Halken, S., et al. Allergy. 2018; 73: 739-743

EAACI guidelines on allergen immunotherapy-Out with the old and in with the new

Agache, I. Allergy. 2018; 73: 737-738